Sutro Q3 Revenue Misses Estimates at $9.1M, Net Loss Widens to $31.5M
STRO sits 34% above its 52-week low of $7.15 on elevated volume (2.2× avg).
Summary
Sutro reported Q3 revenue of $9.098 million against an IBES estimate of $10.3 million, a miss of roughly 12%. The quarter produced an operating loss of $21.956 million on $31.054 million of operating expenses, with net loss of $31.489 million. For a company of this size, a revenue shortfall of this magnitude plus a loss running well above quarterly revenue keeps the cash-burn question front and center. The company had previously extended its cash runway to Q2 2028 after terminating its ATM program in March, so the immediate financing risk is lower than the headline loss suggests, and it reported $142.2M in cash along with a $10M Astellas milestone.
At the time of this announcement, STRO was trading at $9.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159M. The 52-week trading range was $7.15 to $43.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.